Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Our findings suggest that the use of liraglutide and semaglutide in patients who previously underwent MBS can promote significant weight reduction with an acceptable safety profile.
Optimizing ATSB stations to address causes of damage and conducting implementation research to inform optimal delivery and cost-effective deployment will be important to facilitate scale-up of ATSB interventions.
Sarilumab treatment reduced UP and inflammation in Japanese patients with autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)).
The 5-year benefit-risk profile for UPA in RA remains favorable.
This trial will help establish a novel treatment strategy for patients with peripheral clinical stage IA3 pure-solid NSCLC.
In patients with large hypertensive ICH, white matter disease, intraventricular hemorrhage volume, and large reductions in SBP over the first 24 h were independently associated with DWI lesions.
Improvements in global disease activity and skin involvement were significantly greater in children patients treated with apremilast versus placebo.
PEG is superior to ECU and supportive care in hemoglobin, LDH, and FACIT-Fatigue score normalization for patients with PNH and persistent anemia despite ≥3 months of treatment with ECU, and in C5 inhibitor-naive patients.
Data regarding quality of life and patient's acceptance and tolerance of the device will be collected.
Testosterone recovery rate after ADT depends on several factors including hormonal duration, normal baseline T, age and medical comorbidities.
Our exploratory results suggest a potential reduction in the risk of development or worsening of COVID-19 symptoms with ensitrelvir.
Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.
How the body absorbs the medicine parameter prediction as well as predictive performance of the model proofed to be comparable to a separately developed population how the body absorbs the medicine model with 13% deviation in...
Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13...
Conclusions: In this children population aged 7 months to >11 years, AG-920 was therapeutically equivalent to marketed proparacaine with respect to having an ophthalmic examination performed without needing additional local...
The ReSTART trial aims to answer an important question in Radiation Therapy for HNSCC, particularly in a resource-limited setting.
Analysis of immunogenicity data suggested that the percentage of patients positive for AIA antibodies until week 24 was similar and comparable in both the treatment groups, BGL-ASP and RMP; NovoRapid®.
Machine learning analyses of data from the JAVELIN Bladder 100 trial identified potential prognostic and predictive factors for.
There is no apparent difference between PRP and applied to the skin minoxidil 5% solution in the management of AA.
Biosimilar CKD-701 single-drug treatment resulted in comparable visual and anatomical changes to those achieved with reference ranibizumab in PCV eyes.
In these aITCs, glycated haemoglobin and weight reductions were significantly greater for all tirzepatide doses versus semaglutide 0.5 mg with a comparable AE profile.
Our findings suggest that ISSD is a more severe phenotype of the disorder associated with a higher risk of high blood pressure.
This systematic review and meta-analysis provide evidence supporting the association between ankyloglossia and obstructive sleep apnea in children.
Adjunctive pioglitazone treatment in T2DM inadequately controlled with metformin and dapagliflozin demonstrates considerable glycaemic improvement, metabolic benefits, and a low risk of hypoglycaemia.
The PK modeling suggested the optimal dosing regimen based on weight for children patients as: 2-mg QD for patients 10 to <30 kg and 4-mg QD for patients ≥30 kg.
The results show that ivermectin (0.3-0.4 mg/kg), as a treatment for patients with mild COVID-19, is ineffective; however, its safety has been confirmed for participants, including minor participants of 12 years or older.
For belimumab-treated patients, belimumab exposure was not found to be an important predictor of kidney response.
Rotavirus continued to be the leading cause of severe GE in this age group.
Bimekizumab treatment led to early improvements in physical function, sleep, work productivity and overall HRQoL at Week 16 in patients across the full axSpA disease spectrum.
Of the 405 randomized participants (265 men [65.4%]; mean [SD] age, 45.5 [11.0] years; mean [SD] body mass index, 29.5 [4.1]; and mean [SD] HbA1c level, 7.9% [0.6%]), 332 completed the 16-week treatment.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
